Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

Asia map

News and Trends 11 Jan 2023

Biotech in Asia: looking forward to 2023

Masahiko Hayakawa, head of targeted protein degradation at Astellas Pharma Inc., gives us some insights into the state of the biopharma industry in 2023. Astellas is a Japanese headquartered pharmaceutical company active in more than 70 countries around the world. It promotes a ‘focus area approach’ designed to identify opportunities for the continuous creation of […]

January 11, 2023 - 4 minutesmins - By Jim Cornall

2023 science

News and Trends 11 Jan 2023

Lifesciences and biotech in 2023

A Q&A with Bill Coyle, principal, ZS. ZS is a management consulting and technology firm focused on transforming global healthcare. In some ways, 2022 could be seen as a challenging year—at least financially—in biotech. Do you see those trends continuing? Although we see overall sentiments to invest in biotech turning positive in 2023 after a […]

January 11, 2023 - 7 minutesmins - By Jim Cornall

biomaterials being used in tissue engineering such as repairing a heart

In Depth 10 Jan 2023

Innovative biomaterials are revolutionizing tissue regeneration

Scientists are increasingly realizing the potential of biomaterials to help with many tasks. A key area biomaterials are being used in is tissue engineering and regeneration, something several biotechs and academic labs are currently exploring. Biomaterials are materials or substances designed to function in a biological environment, which may or may not be made of […]

January 10, 2023 - 14 minutesmins - By Helen Albert

biotech investments

In Depth 9 Jan 2023

The biggest private biotech investments in December 2022

The companies Apogee Therapeutics, Pulmocide and Qitan Technology bagged the biggest biotech investments in December 2022. Around the world, immunology and manufacturing players attracted the biggest funding rounds. We’ve hit 2023 and a lot of biotech fundraising took place in the final month of 2022. We’ve gathered the biggest biotech investments that went to private […]

January 9, 2023 - 3 minutesmins - By Jonathan Smith

acid alpha-glucosidase GAA

News and Trends 9 Jan 2023

Selecta and Astellas sign LOPD treatment agreement

Selecta Biosciences, Inc. and Astellas Pharma Inc. have announced an exclusive licensing and development agreement for IdeXork (Xork). Xork is being studied as a potential next generation immunoglobulin G (IgG) protease that will be developed by Astellas for use with AT845, an investigational, adeno-associated virus (AAV)-based treatment for late-onset Pompe disease (LOPD) in adults. Pompe […]

January 9, 2023 - 3 minutesmins - By Jim Cornall

monkeypox mpox

News and Trends 9 Jan 2023

BD and CerTest Biotec receive emergency use authorization for mpox test

BD (Becton, Dickinson and Company), and CerTest Biotec have announced emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a molecular polymerase chain reaction (PCR) assay for mpox virus detection. The VIASURE Monkeypox Virus Real Time PCR Reagents for BD MAX System is now available for BD MAX System users. “The […]

January 9, 2023 - 2 minutesmins - By Jim Cornall

ADVERTISEMENT

osteoporosis

News and Trends 9 Jan 2023

Rani Therapeutics provides pipeline update

Rani Therapeutics Holdings, Inc. has completed a pre-investigational new drug (IND) meeting with the U.S. Food and Drug Administration (FDA) with respect to RT-102, the RaniPill GO containing a proprietary formulation of human parathyroid hormone (1-34) analog (PTH) for the potential treatment of osteoporosis, and provided a corporate update. Following feedback from the meeting with […]

January 9, 2023 - 2 minutesmins - By Jim Cornall

covid covid-19

News and Trends 9 Jan 2023

ExeVir Bio secures funding for COVID program

ExeVir Bio, a Belgian biotech company developing nanobody therapies for broad protection against infectious diseases, has secured a venture debt financing agreement of up to €25 million ($26.5 million) with the European Investment Bank (EIB). The EIB financing will help advance ExeVir Bio’s lead asset, XVR012, into clinical trials for COVID-19. ExeVir Bio’s COVID-19 development […]

January 9, 2023 - 3 minutesmins - By Jim Cornall

singapore

News and Trends 9 Jan 2023

BC Platforms to collaborate on Singapore population health study

BC Platforms (BCP) has been selected to analyze and manage data collected from the Health for Life in Singapore (HELIOS) study, which forms part of the SG100K data set for Singapore’s National Precision Medicine program. The HELIOS study is a population cohort study established and led by the Lee Kong Chian School of Medicine (LKCMedicine) […]

January 9, 2023 - 3 minutesmins - By Jim Cornall

cancer

News and Trends 9 Jan 2023

Boehringer Ingelheim and 3T Biosciences to develop next-generation cancer immunotherapies

Boehringer Ingelheim and 3T Biosciences have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune […]

January 9, 2023 - 2 minutesmins - By Jim Cornall

cancer retrovirus

News and Trends 9 Jan 2023

ErVaccine raises €4.5M to start therapeutic cancer vaccine trial

ErVaccine Technologies, announces the closing of a €4.5 million ($4.8 million) seed round, including dilutive and non-dilutive funds, with Seventure and Bpifrance as part of the Aide au Développement de l’Innovation (ADI) program. ErVaccine is a biotech company and spin-off from the Centre Léon Bérard-Centre de Recherche en Cancérologie de Lyon, France, which develops next-generation […]

January 9, 2023 - 3 minutesmins - By Jim Cornall

ovarian cancer

News and Trends 9 Jan 2023

Cartherics granted first patent in China

Cartherics Pty Ltd, a biotechnology company developing immune cell therapies for the treatment of cancer, has been granted a Chinese patent, “Genetically modified cells and uses thereof.” The patent provides a proprietary position for multiple development candidates in Cartherics’ pipeline. Specifically, it covers Cartherics’ chimeric antigen receptor (CAR) targeting tumor-associated glycoprotein-72 (TAG-72), along with T […]

January 9, 2023 - 2 minutesmins - By Jim Cornall

ADVERTISEMENT